Business
At the ASCO® 2026 Annual Meeting, Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced the company will share updated results from the locally advanced cutaneous squamous cell carcinoma (laCSCC) expansion cohort from the pivotal CK-301-101 trial of UNLOXCYT™ (cosibelimab-ipdl) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2026 in Chicago.
About this update from Sun Pharmaceutical Industries Limited
[{"type":"text","content":"Nearly 27% of patients experienced a complete response; median duration of response not reached; only 1 patient experienced a Grade >3 immune-related adverse event","length":166,"tagName":"p","attribs":{}},{"type":"text","content":"Second Largest Prospective Study of Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients ","length":104,"tagName":"p","attribs":{}},{"type":"text","content":"MUMBAI, India and PRINCETON, N.J., May 26, 2026 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced the company will share updated results from the locally advanced cutaneous squamous cell carcinoma (laCSCC) expansion cohort from the pivotal CK-301-101 trial of UNLOXCYT™ (cosibelimab-ipdl) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting on May 31, 2026 in Chicago.","length":560,"tagName":"p"},{"type":"image","alt":"Sun Pharma Logo (PRNewsfoto/Sun Pharma)","displaySize":"","headline":null,"caption":"Sun Pharma Logo (PRNewsfoto/Sun Pharma)","className":"","disableSlideshowImg":false,"size":{"original":{"width":186,"height":250,"url":"https://media.zenfs.com/en/prnewswire.com/ee04a38363603c8f1434148be3e4b701"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_WbvispljTWa2e6ae2HzhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTQ4NA--/https://media.zenfs.com/en/prnewswire.com/ee04a38363603c8f1434148be3e4b701","width":186,"height":250},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/_WbvispljTWa2e6ae2HzhA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTQ4NA--/https://media.zenfs.com/en/prnewswire.com/ee04a38363603c8f1434148be3e4b701","width":186,"height":250}},"href":"https://mma.prnewswire.com/media/2688960/Sun_Pharma_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In the investigator-reviewed data being presented at ASCO, 64 patients with laCSCC received ≥1 dose of UNLOXCYT. The median age of patients in the cohort was 77 years old and 66% were male. This reflects the population commonly seen in clinical practice. Patients received a median of 29 doses over a median treatment duration of 60 weeks. The objective response rate was 50%, including 17 (27%) complete responses and 15 (23%) partial responses. Over a median follow-up o...